Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > ARCHIVE
ARCHIVE
- T-DM1 Significantly Extends PFS in HER2-Positive Metastatic Breast Cancer: Roche
May 23, 2011
- DSP's Development Policy to Focus on Specialty Areas in the US
May 23, 2011
- Results of Dabigatran Sub-Analysis Similar in Japanese Patients vs Overall Study Population
May 23, 2011
- First European Launch of Rivalo in Spain: Kowa
May 23, 2011
- 7 Diseases to Gain Importance in Next 10 Years: JHSF Report
May 23, 2011
- Iberica HD to Expand Clinical Pharmacology Facilities in the US
May 23, 2011
- NBI Stresses Good Cost-effectiveness of Prazaxa
May 23, 2011
- Fuji Yakuhin: Drugstore Division Sales Up 1.4% in FY2010
May 23, 2011
- New Data Confirms Levemir's Efficacy for Type 1 Diabetes in Children Aged 2-5: Novo Nordisk
May 23, 2011
- Takeda Aims for Recovery through Shift toward New Products
May 23, 2011
- Prescriptions Filled by Growell HD Up 40%
May 23, 2011
- 39% of Hospitals Return to Black
May 23, 2011
- Takeda's Patents Cited in Largest Number of Notices of Reasons for Patent Refusal
May 23, 2011
- Teva to Buy 57% Stake in Taiyo for ¥37 Bil.
May 23, 2011
- Domestic Sales of New Drugs Contribute to Growth: Otsuka HD
May 23, 2011
- Daiichi Sankyo: Growth in Sales, Double-digit Rise in Profits
May 23, 2011
- Korosho Asks Kyokai-kenpo to Further Promote Use of Generics
May 23, 2011
- Astellas: Sales, Profits Down on Lower Overseas Sales of Prograf, Harnal
May 23, 2011
- Generics Market Share Up to 23.1% in FY2010 3rd Qtr: JGA
May 23, 2011
- Eisai: Sales Down for First Time in 12 Fiscal Years
May 23, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…